◼ Archived
Business
🔮 fades ✓
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
AstraZeneca's bone disease drug fails Phase 3 trial due to high placebo response.
Astrazeneca
17 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Astrazeneca
This hub groups 17 separate news trends connected to Astrazeneca, spanning July 9, 2026 through October 12, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 124 article observations and 118 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
AstraZeneca pours over $1 billion into a new Cambridge R&D hub, saying it won’t need deals to grow past 2030.
◼ Archived
Business
🔮 fades ✓
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
European drugmakers say they are ‘losing ground’ to US and Chinese rivals
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
AstraZeneca’s flagship oral breast‑cancer pill falters, risking billions in sales and delaying a hoped‑for new therapy
◼ Archived
Business
🔮 fades ✓
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca's COPD drug scores two late-stage trial wins, boosting hopes for a blockbuster treatment.
◼ Archived
Business
🔮 fades ✓
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
◼ Archived
Business
🔮 fades ✓
Alnylam’s heart drug troubles take center stage at a cardiology conference
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments
◼ Archived
Business
🔮 fades ✓
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review
AstraZeneca has abruptly terminated its Phase 3 trial for the lung cancer drug volrustomig, halting development after an internal review.
◼ Archived
Business
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
AstraZeneca's stock surged 6% after a report of merger talks with Bristol Myers Squibb was denied.
◼ Archived
Business
Micron, Bristol Myers, Palantir, Circle Internet, SpaceX, and More Stocks That Explain Today’s Market
Two pharmaceutical giants are in merger talks, potentially reshaping the industry.
◼ Archived
Business
🔮 fades ✓
AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports
AstraZeneca investors react to potential $400 billion merger with Bristol Myers Squibb
◼ Archived
Business
🔮 fades ✓
AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
AstraZeneca and Bristol Myers Squibb are in talks for a $400bn merger, a deal that would reshape the pharmaceutical industry
◼ Archived
Business
🔮 fades ✓
Apple, Amazon, Reddit, Micron, SK Hynix, Roblox, and More Stocks That Explain Today’s Market
Palantir's stock surged over 20% on Tuesday, driving market attention to several key players.
◼ Archived
Business
🔮 fades ✓
Earnings live: AstraZeneca stock rises to kick off a busy earnings week
AstraZeneca stock rises as the company reports second-quarter earnings driven by growth in its cancer drug portfolio.
◼ Archived
Business
🔮 fades ✓
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.